November 15, 2018
BASEL, Switzerland, Nov. 15, 2018 /PR Newswire/ — Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Todd Zavodnick as Chief Executive Officer.
“It is an honor to join Dermavant at such an exciting time in the company’s growth,” said Mr. Zavodnick. “Medical dermatology is a therapeutic area in need of real innovation, and that is precisely what we intend to provide at Dermavant.”
Mr. Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. He joins Dermavant from Revance, a biotechnology company where he served as Chief Commercial Officer and President of Aesthetics and Therapeutics. He previously served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan, at Galderma Laboratories where he was president and general manager of North America and responsible for a portfolio of products generating over $1 billion in annual sales, and at Alcon Laboratories.
“We are thrilled to have Todd join Dermavant as we prepare to initiate our Phase 3 program for tapinarof,” said Frank Torti, M.D., Vant Investment Chair for Roivant Pharma and Chairman of the Board for Dermavant. “Todd’s deep expertise in dermatology will help Dermavant deliver innovative therapies to health care providers and patients worldwide.”
Mr. Zavodnick holds a Master of Business Administration from The University of Texas at Dallas and a Bachelor of Science in Pharmacy from Rutgers University. He is a member of the board of directors of the Children’s Skin Disease Foundation.
Dermavant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for inflammatory skin diseases and medical dermatologic conditions. The company’s existing development pipeline consists of five product candidates targeting five different conditions with significant unmet medical needs. Dermavant’s lead product candidate, tapinarof (DMVT-505), is an investigational topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that is being developed as a potential first-line topical treatment for psoriasis and atopic dermatitis, which affect approximately 7.5 million and 28 million people in the United States, respectively. For more information, please visit www.www.dermavant.com.
About Roivant Pharma
Roivant Pharma is the biopharmaceutical business unit of Roivant Sciences. Roivant Pharma is focused on end-to-end biopharmaceutical company creation, launch, and oversight. Roivant Pharma companies include Myovant, Axovant, Arbutus, Urovant, Enzyvant, Dermavant, Genevant, Metavant, Immunovant, Altavant, and Respivant.
About Roivant Sciences
Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization. We build Vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit www.roivant.com.